Compare · AEMD vs DXCM
AEMD vs DXCM
Side-by-side comparison of Aethlon Medical Inc. (AEMD) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AEMD and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 6230.4x AEMD ($4.7M).
- Over the past year, AEMD is down 99.2% and DXCM is down 10.6% - DXCM leads by 88.6 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 4 for AEMD).
- DXCM has more recent analyst coverage (25 ratings vs 2 for AEMD).
- Company
- Aethlon Medical Inc.
- DexCom Inc.
- Price
- $2.03+2.53%
- $76.59+5.15%
- Market cap
- $4.7M
- $29.57B
- 1M return
- -10.57%
- +25.71%
- 1Y return
- -99.20%
- -10.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 4
- 26
- Recent ratings
- 2
- 25
Aethlon Medical Inc.
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest AEMD
- Aethlon Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Aethlon Medical Inc.
- Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
- Aethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
- SEC Form 4 filed by Gikakis Nicolas
- SEC Form 4 filed by Broenniman Edward G
- SEC Form 4 filed by Rossetti Angela
- SEC Form 4 filed by Shah Chetan
- SEC Form 4 filed by Shah Chetan
- SEC Form 4 filed by Gikakis Nicolas
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)